Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.53 |
| ▸ | BTK | Q06187 | 6/20 | 0.51 |
| ▸ | ITK | Q08881 | 4/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | BLK | P51451 | 1/20 | 0.47 |
| ▸ | BMX | P51813 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16618592 | 0.84 | BTK (0.55) | EGFRBTKTGM2JAK3 | |
| SCHEMBL21275161 | 0.81 | BRD4 (0.50) | EGFRITKSRC | |
| SCHEMBL14912418 | 0.78 | ABL1 (0.43) | EGFRSRC | |
| SCHEMBL21275137 | 0.77 | BTK (0.55) | EGFRBTKBMXJAK3 | |
| SCHEMBL16144748 | 0.77 | BRAF (0.45) | EGFRBTKITKERBB2BLK | |
| SCHEMBL15886528 | 0.76 | BRD4 (0.43) | BTK | |
| SCHEMBL21365439 | 0.76 | EGFR (0.42) | EGFRBTKITKERBB2FYN | |
| SCHEMBL21275233 | 0.75 | BTK (0.42) | EGFRBTKJAK3 | |
| SCHEMBL23165013 | 0.73 | EGFR (0.53) | EGFRJAK3 | |
| SCHEMBL21275167 | 0.73 | JAK2 (0.51) | EGFRBTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160214963-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Beyond Oncology Pharmaceutical LLC (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214963-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Beyond Oncology Pharmaceutical LLC (US) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214963-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, SYK | EGFR 837/4885BTK 1/4885ITK 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.